Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor

Clinical and Developmental Immunology

Volumn 2007, Issue , 2007, Pages

  Van Cruijsen, H ^a   Hoekman, K ^a   Stam, A G M ^a   Van Den Eertwegh, A J M ^a   Kuenen, B C ^a   Scheper, R J ^a   Giaccone, G ^a   De Gruijl, T D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR; 4 ((4 FLUORO 2 METHYL 1H INDOL 5 YL)OXY) 6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINAZOLINE; 4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-(3-(PYRROLIDIN-1-YL)PROPOXY)QUINAZOLINE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD; BONE MARROW CELL; CANCER PATIENT; CELL DIFFERENTIATION; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG DOSE ESCALATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MALE; PLASMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; SUPPRESSOR CELL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MYELOID CELLS; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 37649005055     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2007/17315     Document Type: Article

References (35)

1. J. Banchereau R. M. Steinman Dendritic cells and the control of immunity. Nature 392 6673 1998 245 252
2. D. N. J. Hart Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90 9 1997 3245 3287
3. B. Almand J. R. Resser B. Lindman Clinical significance of defective dendritic cell differentiation in cancer. Clinical Cancer Research 6 5 2000 1755 1766
4. N. Boissel P. Rousselot E. Raffoux Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 18 10 2004 1656 1661
5. S. Della Bella silvia.dellabella@unimi.it M. Gennaro M. Vaccari Altered maturation of peripheral blood dendritic cells in patients with breast cancer. British Journal of Cancer 89 8 2003 1463 1472
6. D. I. Gabrilovich J. Corak I. F. Ciernik D. Kavanaugh D. P. Carbone Decreased antigen presentation by dendritic cells in patients with breast cancer. Clinical Cancer Research 3 3 1997 483 490
7. D. I. Gabrilovich H. L. Chen K. R. Girgis Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medicine 2 10 1996 1096 1103
8. D. I. Gabrilovich dmitry.gabrilovich@mcmail.vanderbilt.edu T. Ishida T. Oyama Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 11 1998 4150 4166
9. S. M. Kiertscher skiertscher@mednet.ucla.edu J. Luo S. M. Dubinett M. D. Roth Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. Journal of Immunology 164 3 2000 1269 1276
10. C. Menetrier-Caux G. Montmain M. C. Dieu Inhibition of the differentiation of dendritic cells from CD 34+ progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92 12 1998 4778 4791
11. C. C. Sombroek A. G. M. Stam A. J. Masterson Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. Journal of Immunology 168 9 2002 4333 4343
12. T. Oyama S. Ran T. Ishida Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. Journal of Immunology 160 3 1998 1224 1232
13. A. Takahashi K. Kono kojikono@yamanshi.ac.jp F. Ichihara H. Sugai H. Fujii Y. Matsumoto Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunology, Immunotherapy 53 6 2004 543 550
14. H. Hurwitz hurwi004@mc.duke.edu L. Fehrenbacher W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 350 23 2004 2335 2342
15. N. Ferrara nf@gene.com Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 25 4 2004 581 611
16. S. R. Wedge steve.wedge@astrazeneca.com J. Kendrew L. F. Hennequin AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Research 65 10 2005 4389 4400
17. P. Therasse pth@eortc.be S. G. Arbuck E. A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 92 3 2000 205 216
18. B. Almand J. I. Clark E. Nikitina Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. Journal of Immunology 166 1 2001 678 689
19. A. Dzionek A. Fuchs P. Schmidt BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. Journal of Immunology 165 11 2000 6037 6046
20. K. P. A. MacDonald D. J. Munster G. J. Clark A. Dzionek J. Schmitz D. N. J. Hart dhart@mmri.mater.org.au Characterization of human blood dendritic cell subsets. Blood 100 13 2002 4512 4520
21. R. Valenti V. Huber P. Filipazzi Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on T lymphocytes. Cancer Research 66 18 2006 9290 9298
22. H. M. W. Verheul K. Hoekman S. Luykx-de Bakker Platelet: transporter of vascular endothelial growth factor. Clinical Cancer Research 3 12 1997 2187 2190
23. J. Drevs drevs@sanafontis.com P. Siegert M. Medinger Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 25 21 2007 3045 3054
24. S. Faivre C. Delbaldo K. Vera Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Journal of Clinical Oncology 24 1 2006 25 35
25. S. Della Bella silvia.dellabella@unimi.it S. Nicola L. Brambilla Quantitative and functional defects of dendritic cells in classic Kaposi's sarcoma. Clinical Immunology 119 3 2006 317 329
26. A. Sciarra sciarrajr@hotmail.com M. Lichtner A. Autran Gomez Characterization of circulating blood dendritic cell subsets DC 123+ (lymphoid) and DC 11 C + (myeloid) in prostate adenocarcinoma patients. Prostate 67 1 2007 1 7
27. P. Allavena Allavena@irfmn.mnegri.it L. Piemonti D. Longoni IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. European Journal of Immunology 28 1 1998 359 369
28. S. Beckebaum susanne.beckebaum@uni-essen.de X. Zhang X. Chen Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clinical Cancer Research 10 21 2004 7260 7269
29. K. Steinbrink M. Wölfl H. Jonuleit J. Knop A. H. Enk Induction of tolerance by IL-10-treated dendritic cells. Journal of Immunology 159 10 1997 4772 4780
30. M. M. Dikov Mikhail.Dikov@vanderbilt.edu J. E. Ohm N. Ray Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. Journal of Immunology 174 1 2005 215 222
31. S. Hiratsuka O. Minowa J. Kuno T. Noda M. Shibuya shibuya@ims.u-tokyo.ac. jp Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proceedings of the National Academy of Sciences of the United States of America 95 16 1998 9349 9354
32. V. Bronte E. Apolloni A. Cabrelle Identification of a CD 11 b + /Gr- 1+ /CD 31+ myeloid progenitor capable of activating or suppressing CD 8+ T cells. Blood 96 12 2000 3838 3846
33. A. S. Pak M. A. Wright J. P. Matthews S. L. Collins G. J. Petruzzelli M. R. I. Young Mechanisms of immune suppression in patients with head and neck cancer: presence of CD 34+ cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clinical Cancer Research 1 1 1995 95 103
34. C. Melani melani@istitutotumori.mi.it C. Chiodoni G. Forni M. P. Colombo Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102 6 2003 2138 2145
35. P. Sinha V. K. Clements S. Ostrand-Rosenberg srosenbe@umbc.edu Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. Journal of Immunology 174 2 2005 636 645